Company Name: Paradigm Biopharmaceuticals
Announcement Date: 07/06/2016
Announcement Category: Awards/recognition
Announcement Content:
BioShares reviews Paradigm Biopharmaceuticals; details of Paradigm's clinical trial
Announcement URL: http://paradigmbiopharma.com/wp-content/uploads/2016/03/2016-03-22-BIOSHARES-640.pdf
About Paradigm Biopharmaceuticals:
Paradigm Biopharmaceuticals (PAR) listed on the ASX in August 2015. We focus on re-purposing pentosan polysulphate sodium (PPS) for new orthopaedic and respiratory applications. We focus on PPS because this FDA-approved drug has a long history of safety and efficacy in treating interstitial cystitis and deep vein thrombosis. Our patents cover new applications in bone marrow edema (BME) and and the allergic inflammatory response in allergic rhinitis (AR), which is commonly known as ‘Hay Fever’.
Go to Company Profile for: Paradigm Biopharmaceuticals
Announcement Contact: [email protected]
